APOBEC3B and non-small cell lung carcinoma: This study implicates A3B and APOBEC mutational signatures as novel predictive biomarkers for checkpoint blockade immunotherapy response in NSCLC and suggests immunotherapy as a novel treatment option for A3B overexpressing NSCLC [133].